Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2020-12-24 | Calendars | Placed on the Union Calendar, Calendar No. 578. | House floor actions |
| 2020-12-24 | Committee | Reported by the Committee on Judiciary. H. Rept. 116-695. | House floor actions |
| 2019-11-21 | Committee | Ordered to be Reported. | House committee actions |
| 2019-11-21 | Committee | Committee Consideration and Mark-up Session Held. | House committee actions |
| 2019-11-19 | Committee | Subcommittee on Antitrust, Commercial, and Administrative Law Discharged. | House committee actions |
| 2019-11-18 | IntroReferral | Referred to the House Committee on the Judiciary. | House floor actions |
| 2019-11-18 | Committee | Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. | House committee actions |
| 2019-11-18 | IntroReferral | Introduced in House | Library of Congress |